Idefirix (Imlifidase)

Idefirix acts as a targeted immunosuppressant for patients undergoing antibody‑mediated transplant preparation.

• HLA‑incompatible kidney transplantation: Enables desensitization by rapidly degrading circulating IgG antibodies, lowering donor‑specific antibody levels and reducing risk of antibody‑mediated rejection.
• Pre‑transplant desensitization: Provides a rapid reduction of sensitizing antibodies, allowing otherwise incompatible donors to become viable.
• Highly sensitized renal transplant candidates: Improves eligibility for transplantation by decreasing panel‑reactive antibody burden.

• Imlifidase is a recombinant protease that specifically cleaves the Fc region of IgG molecules. By catalyzing rapid proteolysis of circulating IgG antibodies, it lowers the concentration of donor‑specific antibodies, thereby diminishing the immune response that can lead to antibody‑mediated rejection in transplantation procedures.

Idefirix may be associated with a range of adverse reactions following intravenous administration.

Common Side Effects

• Infusion‑related reactions: mild fever, chills, or flushing.
• Headache: transient and usually self‑limiting.
• Nausea or mild gastrointestinal discomfort.
• Fatigue or generalized weakness.
• Transient hypotension during infusion.

Serious or Rare Side Effects

• Anaphylaxis or severe allergic reaction.
• Cytokine release syndrome with high fever and hypotension.
• Severe infections due to profound immunosuppression.
• Thromboembolic events such as deep vein thrombosis.
• Acute renal impairment.
• Immune complex–mediated vasculitis.

Prior to initiating Idefirix therapy, several safety considerations should be observed.

• Assess donor‑specific antibody levels: confirm the need for desensitization.
• Monitor vital signs and infusion reactions continuously during administration.
• Avoid use in patients with known hypersensitivity to recombinant proteases.
• Evaluate infection risk: defer treatment in active uncontrolled infections.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Idefirix can interact with other agents that modify immune function or hemostasis.

Major Interactions (Avoid)

• Concurrent potent immunosuppressants: may markedly increase infection risk.
• Live vaccines: risk of uncontrolled infection due to immunosuppression.
• Plasma exchange therapy performed shortly after infusion: may reduce drug efficacy.

Moderate Interactions (Monitor Closely)

• Anticoagulants (e.g., warfarin, heparin): monitor for bleeding complications.
• Systemic corticosteroids: may augment overall immunosuppressive effect.
• Cytokine‑targeting agents (e.g., tocilizumab): may alter immune response dynamics.